Back to search results

Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes

Abroad (travel likely)Recruiting

Conditions

Chronic Obstructive Pulmonary Disease COPD

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Investigational Site Number : 2500021, Aix-en-Provence, France

  • Investigational Site Number : 2500043, Blois, France

  • Investigational Site Number : 2500044, Brest, France

  • Investigational Site Number : 2500009, Colmar, France

  • Investigational Site Number : 2500031, Contamine-sur-Arve, France

  • Investigational Site Number : 2500022, Juan-les-Pins, France

  • Investigational Site Number : 2500020, Le Chesnay, France

  • Investigational Site Number : 2500038, Libourne, France

  • Investigational Site Number : 2500033, Lyon, France

  • Investigational Site Number : 2500024, Marseille, France

  • Investigational Site Number : 2500002, Montpellier, France

  • Investigational Site Number : 2500047, Morlaix, France

  • Investigational Site Number : 2500040, Niort, France

  • Investigational Site Number : 2500026, Nîmes, France

  • Investigational Site Number : 2500017, Paris, France

  • Investigational Site Number : 2500001, Pessac, France

  • Investigational Site Number : 2500034, Pierre-Bénite, France

  • Investigational Site Number : 2500048, Saint-Pierre, France

  • Investigational Site Number : 2500028, Toulouse, France

  • Investigational Site Number : 2500029, Toulouse, France

  • Investigational Site Number : 2500010, Vantoux, France

  • Investigational Site Number : 2500035, Villeurbanne, France

View source on ClinicalTrials.gov(opens in a new tab)